Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Equity Average (2019 - 2023)

Historic Equity Average for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to $56.7 billion.

  • ADC Therapeutics' Equity Average fell 2128.48% to $56.7 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $56.7 billion, marking a year-over-year decrease of 2128.48%. This contributed to the annual value of $42.3 billion for FY2022, which is N/A changed from last year.
  • ADC Therapeutics' Equity Average amounted to $56.7 billion in Q3 2023, which was down 2128.48% from $59.3 billion recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Equity Average peaked at $77.3 billion during Q2 2022, and registered a low of $91997.0 during Q3 2021.
  • In the last 3 years, ADC Therapeutics' Equity Average had a median value of $37.4 billion in 2022 and averaged $37.0 billion.
  • In the last 5 years, ADC Therapeutics' Equity Average skyrocketed by 8097615371.28% in 2022 and then tumbled by 2408.41% in 2023.
  • Quarter analysis of 3 years shows ADC Therapeutics' Equity Average stood at $59.7 million in 2021, then soared by 57963.41% to $34.7 billion in 2022, then soared by 63.34% to $56.7 billion in 2023.
  • Its Equity Average was $56.7 billion in Q3 2023, compared to $59.3 billion in Q2 2023 and $30.4 billion in Q1 2023.